United States - English - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 250 mg - clarithromycin tablets, usp and clarithromycin for oral suspension, usp are indicated for the treatment of mild to moderate infections caused by susceptible isolates of the designated bacteria in the conditions as listed below: adults (clarithromycin immediate-release tablets and clarithromycin for oral suspension) pharyngitis/tonsillitis due to streptococcus pyogenes (the usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. clarithromycin is generally effective in the eradication of s. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present). acute maxillary sinusitis due to haemophilus influenzae , moraxella catarrhalis, or streptococcus pneumoniae. acute bacterial exacerbation of chronic bronchitis due to haemophilus influenzae , haemophilus parainfluenzae

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - clarithromycin 250mg; clarithromycin 250mg - film coated tablet - 250 mg - active: clarithromycin 250mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose iron oxide yellow macrogol 8000 magnesium stearate microcrystalline cellulose titanium dioxide active: clarithromycin 250mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose iron oxide yellow macrogol 8000 magnesium stearate microcrystalline cellulose titanium dioxide - clarithromycin is indicated for treatment of infections caused by susceptible organisms. such infections include: 1. respiratory tract infections including bronchitis, pneumonia, tonsillitis, sinusitis and pharyngitis. 2. skin and soft tissue infections such as folliculitis, cellulitis and erysipelas. 3. disseminated or localized mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare. localized infections due to mycobacterium chelonae, mycobacterium fortuitum or mycobacterium kansasii. 4. prevention of disseminated mycobacterium avium complex infection in hiv-infected patients with cd4 lymphocyte counts less than or equal to 100/mm3.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - clarithromycin 500mg; clarithromycin 500mg - film coated tablet - 500 mg - active: clarithromycin 500mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose iron oxide yellow macrogol 8000 magnesium stearate microcrystalline cellulose titanium dioxide active: clarithromycin 500mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose iron oxide yellow macrogol 8000 magnesium stearate microcrystalline cellulose titanium dioxide - clarithromycin is indicated for treatment of infections caused by susceptible organisms. such infections include: 1. respiratory tract infections including bronchitis, pneumonia, tonsillitis, sinusitis and pharyngitis. 2. skin and soft tissue infections such as folliculitis, cellulitis and erysipelas. 3. disseminated or localized mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare. localized infections due to mycobacterium chelonae, mycobacterium fortuitum or mycobacterium kansasii. 4. prevention of disseminated mycobacterium avium complex infection in hiv-infected patients with cd4 lymphocyte counts less than or equal to 100/mm3.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - clarithromycin, quantity: 250 mg - tablet, film coated - excipient ingredients: titanium dioxide; powdered cellulose; magnesium stearate; hypromellose; macrogol 4000; croscarmellose sodium; microcrystalline cellulose; colloidal anhydrous silica; lactose monohydrate - clarithromycin sandoz clarithromycin is indicated for use in adults and children older than 12 years for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro-organisms in the conditions listed below: acute streptococcal pharyngitis; community acquired pneumonia due to chlamydia pneumoniae, mycoplasma pneumoniae, legionella pneumophilia and streptococcus pneumoniae;uncomplicated skin and skin structure infections due to staphylococcus aureus or streptococcus pyogenes;disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare and skin and skin structure infections due to mycobacterium chelonae. clarithromycin should be used in combination with other anti mycobacterial agents.prevention of disseminated mycobacterium avium complex infection in hiv infected adults with cd4 lymphocyte counts <75 cells/mm 3 (see precautions). disseminated infection due to mycobacterium avium complex should be excluded by a negat

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - clarithromycin, quantity: 500 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; colloidal anhydrous silica; croscarmellose sodium; macrogol 4000; hypromellose; titanium dioxide; microcrystalline cellulose; powdered cellulose - clarithromycin sandoz clarithromycin is indicated for use in adults and children older than 12 years for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro-organisms in the conditions listed below: acute streptococcal pharyngitis; community acquired pneumonia due to chlamydia pneumoniae, mycoplasma pneumoniae, legionella pneumophilia and streptococcus pneumoniae;uncomplicated skin and skin structure infections due to staphylococcus aureus or streptococcus pyogenes;disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare and skin and skin structure infections due to mycobacterium chelonae. clarithromycin should be used in combination with other anti mycobacterial agents.prevention of disseminated mycobacterium avium complex infection in hiv infected adults with cd4 lymphocyte counts <75 cells/mm 3 (see precautions). disseminated infection due to mycobacterium avium complex should be excluded by a negat

United States - English - NLM (National Library of Medicine)

avpak - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 250 mg - clarithromycin tablets, usp are indicated for the treatment of mild to moderate infections caused by susceptible isolates of the designated bacteria in the conditions as listed below: pharyngitis/tonsillitis due to streptococcus pyogenes (the usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. clarithromycin is generally effective in the eradication of s. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present). acute maxillary sinusitis due to haemophilus influenzae , moraxella catarrhalis, or streptococcus pneumoniae. acute bacterial exacerbation of chronic bronchitis due to haemophilus influenzae , haemophilus parainfluenzae , moraxella catarrhalis , or streptococcus pneumoniae. community-acquired pneumonia due to haemophilus influenzae , mycoplasma pneumoniae , streptococcus pneumoniae , or chlamydophila pneumoniae (twar). uncomplicated skin and skin structure infections due to staphylococcus aureus , or streptococcus pyogenes (abscesses usually require surgical drainage). disseminated mycobacterial infections due to mycobacterium avium , or mycobacterium intracellulare clarithromycin tablets, usp in combination with amoxicillin and prevacid (lansoprazole) or prilosec (omeprazole) delayed-release capsules, as triple therapy, are indicated for the treatment of patients with helicobacter pylori  infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate h. pylori . clarithromycin tablets, usp in combination with prilosec (omeprazole) capsules or tritec (ranitidine bismuth citrate) tablets are also indicated for the treatment of patients with an active duodenal ulcer associated with h. pylori   infection. however, regimens which contain clarithromycin as the single antimicrobial agent are more likely to be associated with the development of clarithromycin resistance among patients who fail therapy. clarithromycin-containing regimens should not be used in patients with known or suspected clarithromycin resistant isolates because the efficacy of treatment is reduced in this setting. in patients who fail therapy, susceptibility testing should be done if possible. if resistance to clarithromycin is demonstrated, a non-clarithromycin-containing therapy is recommended. (for information on development of resistance see microbiology   section.) the eradication of h. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence. pharyngitis/tonsillitis due to streptococcus pyogenes. community-acquired pneumonia due to mycoplasma pneumoniae , streptococcus pneumoniae , or chlamydophila pneumoniae (twar) acute maxillary sinusitis due to haemophilus influenzae , moraxella catarrhalis , or streptococcus pneumoniae acute otitis media due to haemophilus influenzae , moraxella catarrhalis , or streptococcus pneumoniae note: for information on otitis media, see clinical studies - otitis media. uncomplicated skin and skin structure infections due to staphylococcus aureus , or streptococcus pyogenes (abscesses usually require surgical drainage.) disseminated mycobacterial infections due to mycobacterium avium , or mycobacterium intracellulare clarithromycin tablets, usp are indicated for the prevention of disseminated mycobacterium avium complex (mac) disease in patients with advanced hiv infection. to reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin and other antibacterial drugs, clarithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. clarithromycin tablets are contraindicated in patients with a known hypersensitivity to clarithromycin or any of its excipients, erythromycin, or any of the macrolide antibiotics. clarithromycin tablets are contraindicated in patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of clarithromycin. concomitant administration of clarithromycin and any of the following drugs is contraindicated: cisapride, pimozide, astemizole, terfenadine, and ergotamine or dihydroergotamine (see drug interactions ). there have been post-marketing reports of drug interactions when clarithromycin and/or erythromycin are coadministered with cisapride, pimozide, astemizole, or terfenadine resulting in cardiac arrhythmias (qt prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes) most likely due to inhibition of metabolism of these drugs by erythromycin and clarithromycin. fatalities have been reported. concomitant administration of clarithromycin and colchicine is contraindicated in patients with renal or hepatic impairment. clarithromycin should not be given to patients with history of qt prolongation or ventricular cardiac arrhythmia, including torsades de pointes . clarithromycin should not be used concomitantly with hmg-coa reductase inhibitors (statins) that are extensively metabolized by cyp3a4 (lovastatin or simvastatin), due to the increased risk of myopathy, including rhabdomyolysis (see warnings ). for information about contraindications of other drugs indicated in combination with clarithromycin tablets, refer to the contraindications  section of their package inserts.

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 500 mg - clarithromycin tablets are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae , haemophilus parainfluenzae , moraxella catarrhalis , or streptococcus pneumoniae [see indications and usage (1.9)] . clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae , moraxella catarrhalis , or streptococcus pneumoniae [see indications and usage (1.9)] . clarithromycin tablets are indicated [see indications and usage (1.9)] for the treatment of mild to moderate infections caused by susceptible isolates due to: clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to streptococcus pyogenes as an alternative in individuals who cannot use first line therapy. clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to staphylococ

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 500 mg - clarithromycin tablets, usp are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae , haemophilus parainfluenzae , moraxella catarrhalis , or streptococcus pneumoniae [see indications and usage (1.9)] . clarithromycin tablets, usp are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae , moraxella catarrhalis , or streptococcus pneumoniae [see indications and usage (1.9)] . clarithromycin tablets, usp are indicated [see indications and usage (1.9)] for the treatment of mild to moderate infections caused by susceptible isolates due to: - haemophilus influenzae (in adults) - mycoplasma pneumoniae , streptococcus pneumoniae , chlamydophila pneumoniae clarithromycin tablets, usp are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to streptococcus pyogenes as an alternative in individuals who cannot use first line ther

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 500 mg - clarithromycin tablets are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae, haemophilus parainfluenzae, moraxella catarrhalis, or streptococcus pneumoniae [see indications and usage (1.9)]. clarithromycin tablets (in adults) are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae, moraxella catarrhalis, or streptococcus pneumoniae [see indications and usage (1.9)]. clarithromycin tablets are indicated [see indications and usage (1.9)] for the treatment of mild to moderate infections caused by susceptible isolates due to: - haemophilus influenzae (in adults) - mycoplasma pneumoniae, streptococcus pneumoniae, chlamydophila pneumoniae (in adults and pediatric patients) clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to streptococcus pyogenes as an alternative in individuals who canno

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 500 mg - clarithromycin tablets are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae , haemophilus parainfluenzae , moraxella catarrhalis , or streptococcus pneumoniae. clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae , moraxella catarrhalis , or streptococcus pneumoniae. clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to: clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to streptococcus pyogenes as an alternative in individuals who cannot use first line therapy. clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to staphylococcus aureus , or streptococcus pyogenes . clarithromycin tablets are indicated in pediatric patients for t